← Back to Screener
Beta Bionics, Inc. Common Stock (BBNX)
Price$13.89
Value ScoreC
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-63.60%
Price vs S&P 500 (4W)43.95%
VGM Score62.37
Market Capitalization$618.96M
All Metrics
Book Value / Share (Quarterly)$6.09
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)724.29%
Cash Flow / Share (Quarterly)$-1.37
Price vs S&P 500 (YTD)-62.57%
Gross Margin (TTM)57.15%
Net Profit Margin (TTM)-60.27%
EPS (TTM)$-1.51
10-Day Avg Trading Volume0.85M
EPS Excl Extra (TTM)$-1.51
EPS (Annual)$-1.81
ROI (Annual)-25.45%
Gross Margin (Annual)55.40%
Cash / Share (Quarterly)$4.48
Revenue Growth QoQ (YoY)56.62%
ROA (Last FY)-22.27%
EBITD / Share (TTM)$-1.72
Operating Margin (TTM)-70.13%
Cash Flow / Share (Annual)$-1.27
P/B Ratio2.28x
P/B Ratio (Quarterly)1.65x
Net Income / Employee (Annual)$-174,300
EV / Revenue (TTM)5.34x
ROA (TTM)-20.55%
EPS Incl Extra (Annual)$-1.81
Current Ratio (Annual)8.66x
Quick Ratio (Quarterly)9.39x
3-Month Avg Trading Volume1.05M
52-Week Price Return-28.95%
Revenue / Employee (TTM)$262,500
P/S Ratio (Annual)6.17x
Asset Turnover (Annual)0.30x
52-Week High$32.71
EPS Excl Extra (Annual)$-1.81
26-Week Price Return-55.68%
Quick Ratio (Annual)7.73x
13-Week Price Return25.02%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.69x
Enterprise Value$588.76M
Asset Turnover (TTM)0.34x
Revenue / Employee (Annual)$238,700
Inventory Turnover (Annual)2.55x
Pretax Margin (Annual)-73.02%
Cash / Share (Annual)$4.94
3-Month Return Std Dev81.69%
Net Income / Employee (TTM)$-158,200
ROE (Last FY)-25.45%
EPS Basic Excl Extra (Annual)$-1.81
Receivables Turnover (TTM)8.18x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.51
Receivables Turnover (Annual)6.34x
ROI (TTM)-23.00%
P/S Ratio (TTM)5.61x
Revenue / Share (Annual)$2.47
Price vs S&P 500 (52W)-53.32%
Year-to-Date Return-54.41%
5-Day Price Return8.52%
EPS Normalized (Annual)$-1.81
Net Profit Margin (Annual)-73.02%
Month-to-Date Return14.60%
EBITD / Share (Annual)$-1.73
Operating Margin (Annual)-71.50%
EPS Basic Excl Extra (TTM)$-1.51
P/B Ratio (Annual)4.66x
Inventory Turnover (TTM)2.39x
Pretax Margin (TTM)-60.27%
Book Value / Share (Annual)$6.48
Price vs S&P 500 (13W)16.77%
Beta0.90x
Revenue / Share (TTM)$2.48
ROE (TTM)-23.00%
52-Week Low$8.80
vGradeC
gGradeA
mGradeC
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.49est. -0.50
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.12
4.11
4.11
4.11
Industry Peers — Surgical & Medical Instruments(138)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BBNXBeta Bionics, Inc. Common Stock | C | A | C | $13.89 |
| SYKStryker Corporation | C | C | C | $305.66 |
| MMM3M Company | C | F | C | $153.76 |
| BSXBoston Scientific Corp. | C | B | D | $48.55 |
| MDLNMedline Inc. Class A common stock | C | D | D | $33.61 |
| BDXBecton, Dickinson and Co. | B | C | C | $151.16 |
| RMDResMed Inc. | C | B | C | $196.04 |
| DXCMDexCom, Inc. | C | B | C | $72.86 |
| WSTWest Pharmaceutical Services, Inc. | D | C | B | $314.50 |
| SOLVSolventum Corporation | C | D | B | $81.01 |
| PENPenumbra, Inc. | F | C | B | $320.53 |
About
Beta Bionics is a commercial-stage medical device company developing the iLet Bionic Pancreas, an automated insulin delivery system using adaptive closed-loop algorithms for people with insulin-dependent diabetes. The company's proprietary technology is designed to simplify diabetes management and improve patient outcomes by automating insulin dosing. Beta Bionics operates a focused business model centered on the development, manufacturing, and commercialization of the iLet platform.